Does ENCORAFENIB Cause Malignant neoplasm progression? 160 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 160 reports of Malignant neoplasm progression have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 1.9% of all adverse event reports for ENCORAFENIB.
160
Reports of Malignant neoplasm progression with ENCORAFENIB
1.9%
of all ENCORAFENIB reports
65
Deaths
58
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ENCORAFENIB?
Of the 160 reports, 65 (40.6%) resulted in death, 58 (36.3%) required hospitalization, and 10 (6.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 160 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Neoplasm progression (548)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ENCORAFENIB Alternatives Have Lower Malignant neoplasm progression Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN